BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 31403177)

  • 1. Progesterone receptor status modifies the association between body mass index and prognosis in women diagnosed with estrogen receptor positive breast cancer.
    Oudanonh T; Nabi H; Ennour-Idrissi K; Lemieux J; Diorio C
    Int J Cancer; 2020 May; 146(10):2736-2745. PubMed ID: 31403177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinicopathological Characteristics and Breast Cancer-Specific Survival of Patients With Single Hormone Receptor-Positive Breast Cancer.
    Li Y; Yang D; Yin X; Zhang X; Huang J; Wu Y; Wang M; Yi Z; Li H; Li H; Ren G
    JAMA Netw Open; 2020 Jan; 3(1):e1918160. PubMed ID: 31899528
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Body weight at age 20 years, subsequent weight change and breast cancer risk defined by estrogen and progesterone receptor status--the Japan public health center-based prospective study.
    Suzuki R; Iwasaki M; Inoue M; Sasazuki S; Sawada N; Yamaji T; Shimazu T; Tsugane S;
    Int J Cancer; 2011 Sep; 129(5):1214-24. PubMed ID: 21064092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High fasting blood glucose and obesity significantly and independently increase risk of breast cancer death in hormone receptor-positive disease.
    Minicozzi P; Berrino F; Sebastiani F; Falcini F; Vattiato R; Cioccoloni F; Calagreti G; Fusco M; Vitale MF; Tumino R; Sigona A; Budroni M; Cesaraccio R; Candela G; Scuderi T; Zarcone M; Campisi I; Sant M
    Eur J Cancer; 2013 Dec; 49(18):3881-8. PubMed ID: 24011933
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adiposity, hormone replacement therapy use and breast cancer risk by age and hormone receptor status: a large prospective cohort study.
    Ritte R; Lukanova A; Berrino F; Dossus L; Tjønneland A; Olsen A; Overvad TF; Overvad K; Clavel-Chapelon F; Fournier A; Fagherazzi G; Rohrmann S; Teucher B; Boeing H; Aleksandrova K; Trichopoulou A; Lagiou P; Trichopoulos D; Palli D; Sieri S; Panico S; Tumino R; Vineis P; Quirós JR; Buckland G; Sánchez MJ; Amiano P; Chirlaque MD; Ardanaz E; Sund M; Lenner P; Bueno-de-Mesquita B; van Gils CH; Peeters PH; Krum-Hansen S; Gram IT; Lund E; Khaw KT; Wareham N; Allen NE; Key TJ; Romieu I; Rinaldi S; Siddiq A; Cox D; Riboli E; Kaaks R
    Breast Cancer Res; 2012 May; 14(3):R76. PubMed ID: 22583394
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Relationship between body mass index and the expression of hormone receptors or human epidermal growth factor receptor 2 with respect to breast cancer survival.
    Jeon YW; Kang SH; Park MH; Lim W; Cho SH; Suh YJ
    BMC Cancer; 2015 Nov; 15():865. PubMed ID: 26546331
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer.
    Bae SY; Kim S; Lee JH; Lee HC; Lee SK; Kil WH; Kim SW; Lee JE; Nam SJ
    BMC Cancer; 2015 Mar; 15():138. PubMed ID: 25880075
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention.
    Wang F; Liu L; Cui S; Tian F; Fan Z; Geng C; Cao X; Yang Z; Wang X; Liang H; Wang S; Jiang H; Duan X; Wang H; Li G; Wang Q; Zhang J; Jin F; Tang J; Li L; Zhu S; Zuo W; Ma Z; Zhou F; Yu L; Xiang Y; Li L; Shen S; Yu Z
    Oncologist; 2017 Dec; 22(12):1431-1443. PubMed ID: 28912152
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hip circumference is associated with the risk of premenopausal ER-/PR- breast cancer.
    Fagherazzi G; Chabbert-Buffet N; Fabre A; Guillas G; Boutron-Ruault MC; Mesrine S; Clavel-Chapelon F
    Int J Obes (Lond); 2012 Mar; 36(3):431-9. PubMed ID: 21427693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Body weight and postmenopausal breast cancer risk defined by estrogen and progesterone receptor status among Swedish women: A prospective cohort study.
    Suzuki R; Rylander-Rudqvist T; Ye W; Saji S; Wolk A
    Int J Cancer; 2006 Oct; 119(7):1683-9. PubMed ID: 16646051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adult body size and physical activity in relation to risk of breast cancer according to tumor androgen receptor status.
    Zhang X; Eliassen AH; Tamimi RM; Hazra A; Beck AH; Brown M; Collins LC; Rosner B; Hankinson SE
    Cancer Epidemiol Biomarkers Prev; 2015 Jun; 24(6):962-8. PubMed ID: 25855627
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Breast cancer-specific survival by clinical subtype after 7 years follow-up of young and elderly women in a nationwide cohort.
    Johansson ALV; Trewin CB; Hjerkind KV; Ellingjord-Dale M; Johannesen TB; Ursin G
    Int J Cancer; 2019 Mar; 144(6):1251-1261. PubMed ID: 30367449
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis.
    Ma H; Ursin G; Xu X; Lee E; Togawa K; Malone KE; Marchbanks PA; McDonald JA; Simon MS; Folger SG; Lu Y; Sullivan-Halley J; Deapen DM; Press MF; Bernstein L
    Breast Cancer Res; 2018 Jan; 20(1):5. PubMed ID: 29357906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of body mass index on survival outcome among women with early stage triple-negative breast cancer.
    Dawood S; Lei X; Litton JK; Buchholz TA; Hortobagyi GN; Gonzalez-Angulo AM
    Clin Breast Cancer; 2012 Oct; 12(5):364-72. PubMed ID: 23040004
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast Cancer Survival Analysis Based on Immunohistochemistry Subtypes (ER/PR/HER2): a Retrospective Cohort Study.
    Poorolajal J; Nafissi N; Akbari ME; Mahjub H; Esmailnasab N; Babaee E
    Arch Iran Med; 2016 Oct; 19(10):680-686. PubMed ID: 27743431
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Racial/Ethnic Disparities in Survival after Breast Cancer Diagnosis by Estrogen and Progesterone Receptor Status: A Pooled Analysis.
    John EM; McGuire V; Kurian AW; Koo J; Shariff-Marco S; Gomez SL; Cheng I; Keegan THM; Kwan ML; Bernstein L; Vigen C; Wu AH
    Cancer Epidemiol Biomarkers Prev; 2021 Feb; 30(2):351-363. PubMed ID: 33355191
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Body size and breast cancer prognosis in relation to hormone receptor and menopausal status: a meta-analysis.
    Niraula S; Ocana A; Ennis M; Goodwin PJ
    Breast Cancer Res Treat; 2012 Jul; 134(2):769-81. PubMed ID: 22562122
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Postmenopausal obesity as a breast cancer risk factor according to estrogen and progesterone receptor status (Japan).
    Yoo K; Tajima K; Park S; Kang D; Kim S; Hirose K; Takeuchi T; Miura S
    Cancer Lett; 2001 Jun; 167(1):57-63. PubMed ID: 11323099
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The associations of obesity, lymph node status and prognosis in breast cancer patients: dependence on estrogen and progesterone receptor status.
    Maehle BO; Tretli S; Thorsen T
    APMIS; 2004 Jun; 112(6):349-57. PubMed ID: 15511272
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk factors for hormone receptor-defined breast cancer in postmenopausal women.
    Rosenberg LU; Einarsdóttir K; Friman EI; Wedrén S; Dickman PW; Hall P; Magnusson C
    Cancer Epidemiol Biomarkers Prev; 2006 Dec; 15(12):2482-8. PubMed ID: 17164374
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.